Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT

Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid Leukemia

(2016) Celalettin Ustun et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial

(2016) Charles Craddock et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Using Minimal Residual Disease to Improve Treatment Response Definitions and Hematopoietic Cell Transplantation Strategy in Acute Leukemia

(2016) Renato Bassan   JOURNAL OF CLINICAL ONCOLOGY

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease–Based Definition of Complete Remission?

(2016) Daisuke Araki et al.   JOURNAL OF CLINICAL ONCOLOGY

Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial

(2016) Irwin Walker et al.   LANCET ONCOLOGY

Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease

(2016) Nicolaus Kröger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation

(2015) A. Tschan-Plessl et al.   ANNALS OF HEMATOLOGY

Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study

(2015) Nelli Bejanyan et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation

(2015) C. Schmid et al.   BLOOD

Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation

(2015) Z Jedlickova et al.   BONE MARROW TRANSPLANTATION

High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation

(2015) Tiago De Freitas et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT

(2015) B. N. Savani et al.   HAEMATOLOGICA

Droplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation

(2015) Chiara Brambati et al.   HAEMATOLOGICA

Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502

(2015) Steven M. Devine et al.   JOURNAL OF CLINICAL ONCOLOGY

Optimal time-points for minimal residual disease monitoring change on the basis of the method used in patients with acute myeloid leukemia who underwent allogeneic stem cell transplantation: A comparison between multiparameter flow cytometry and Wilms’ tumor 1 expression

(2015) Giovanni Rossi et al.   LEUKEMIA RESEARCH

Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT

(2015) B. N. Savani et al.   HAEMATOLOGICA

Droplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation

(2015) Chiara Brambati et al.   HAEMATOLOGICA

Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia

(2014) Yi-Bin Chen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation

(2014) R. F. Schlenk et al.   BLOOD

In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification

(2014) Y. Wang et al.   BLOOD

Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation

(2014) Mariana Bastos-Oreiro et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation

(2014) Rafael Bejar et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation

(2014) R B Walter et al.   LEUKEMIA

Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation

(2014) L Crucitti et al.   LEUKEMIA

Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis

(2014) M Stern et al.   LEUKEMIA

Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34+ donor cell chimerism analysis

(2013) Joerg Christian Hoffmann et al.   ANNALS OF HEMATOLOGY

Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity

(2013) Xiao-su Zhao et al.   ANNALS OF HEMATOLOGY

Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part III. Prevention and Treatment of Relapse after Allogeneic Transplantation

(2013) Marcos de Lima et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML

(2013) N. Shayegi et al.   BLOOD

CD34+ lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT

(2013) F Rosenow et al.   BONE MARROW TRANSPLANTATION

Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update

(2013) Bei Hu et al.   Expert Review of Hematology

Risk-adapted donor lymphocyte infusion based on chimerism and donor source in pediatric leukemia

(2013) P Rujkijyanont et al.   Blood Cancer Journal

High Alloreactivity of Low-Dose Prophylactic Donor Lymphocyte Infusion in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation with an Alemtuzumab-Containing Conditioning Regimen

(2012) Maria Liga et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia

(2012) W. Leung et al.   BLOOD

Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q-

(2012) J. M. Middeke et al.   BLOOD

Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation

(2012) C.-H. Yan et al.   BLOOD

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

(2012) J. A. L. Yin et al.   BLOOD

Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with

(2012) R Martino et al.   BONE MARROW TRANSPLANTATION

Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia

(2012) S A Buckley et al.   BONE MARROW TRANSPLANTATION

Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse

(2012) T. Pfeiffer et al.   HAEMATOLOGICA

Comparative Outcomes of Donor Graft CD34+Selection and Immune Suppressive Therapy As Graft-Versus-Host Disease Prophylaxis for Patients With Acute Myeloid Leukemia in Complete Remission Undergoing HLA-Matched Sibling Allogeneic Hematopoietic Cell Transplantation

(2012) Marcelo C. Pasquini et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis

(2012) Salut Brunet et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparative Analysis of the Value of Allogeneic Hematopoietic Stem-Cell Transplantation in Acute Myeloid Leukemia With Monosomal Karyotype Versus Other Cytogenetic Risk Categories

(2012) Jan J. Cornelissen et al.   JOURNAL OF CLINICAL ONCOLOGY

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial

(2012) Martin Bornhäuser et al.   LANCET ONCOLOGY

Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia

(2012) M van Gelder et al.   LEUKEMIA

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses

(2012) S K Metzelder et al.   LEUKEMIA

Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia

(2012) H Pfeifer et al.   LEUKEMIA

The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

(2012) Jan J. Cornelissen et al.   Nature Reviews Clinical Oncology

Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation

(2011) M. Fang et al.   BLOOD

Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation

(2011) C. Schmid et al.   BLOOD

Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation

(2011) E. Rettinger et al.   BLOOD

Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS

(2011) S M Luger et al.   BONE MARROW TRANSPLANTATION

Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis

(2011) Y Wang et al.   BONE MARROW TRANSPLANTATION

Early allo-SCT for AML with a complex aberrant karyotype—results from a prospective pilot study

(2011) C Schmid et al.   BONE MARROW TRANSPLANTATION

Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

(2011) Roland B. Walter et al.   JOURNAL OF CLINICAL ONCOLOGY

Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia

(2011) C Craddock et al.   LEUKEMIA

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

(2011) U Platzbecker et al.   LEUKEMIA

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, Acute Leukemias, and Myelodysplastic Syndromes

(2010) Nicolaus Kröger et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome

(2010) Marcos de Lima et al.   CANCER

Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia

(2010) Anna Candoni et al.   CLINICAL TRANSPLANTATION

Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure

(2010) Michel Duval et al.   JOURNAL OF CLINICAL ONCOLOGY

Quantifying the Survival Benefit for Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed Acute Myelogenous Leukemia

(2009) Paul M. Armistead et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Risk score for outcome after allogeneic hematopoietic stem cell transplantation

(2009) Alois Gratwohl et al.   CANCER

Allogeneic stem cell transplantation after reduced-intensity conditioning for acute myeloid leukaemia: impact of chronic graft-versus-host disease

(2009) David Valcárcel et al.   CURRENT OPINION IN ONCOLOGY

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation

(2009) Luca Vago et al.   NEW ENGLAND JOURNAL OF MEDICINE

Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies

(2008) María Díez-Campelo et al.   AMERICAN JOURNAL OF HEMATOLOGY

Graft-versus-leukemia effects of transplantation and donor lymphocytes

(2008) H.-J. Kolb   BLOOD

Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation

(2008) Mohamed Sorror et al.   CANCER

Modified Donor Lymphocyte Infusion (DLI) for the Prophylaxis of Leukemia Relapse after Hematopoietic Stem Cell Transplantation in Patients with Advanced Leukemia—Feasibility and Safety Study

(2008) Xiao-Jun Huang et al.   JOURNAL OF CLINICAL IMMUNOLOGY